Tipranavir

Chemical formula: C₃₁H₃₃F₃N₂O₅S  Molecular mass: 602.664 g/mol  PubChem compound: 54682461

Therapeutic indications

Tipranavir is indicated for:

HIV-1 infection

Population group: only adolescents (12 years - 18 years old) , adults (18 - 65 years old)

Tipranavir, co-administered with low dose ritonavir, is indicated for combination antiretroviral treatment of HIV-1 infection in highly pre-treated adults and adolescents 12 years of age or older with virus resistant to multiple protease inhibitors. Tipranavir should only be used as part of an active combination antiretroviral regimen in patients with no other therapeutic options.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Tipranavir is contraindicated in the following cases:

Moderate or severe (Child-Pugh Class B or C) hepatic impairment

at least one of
Hepatic failure stage III
Hepatic failure stage IV

Colchicine, renal impairment, hepatic impairment

Colchicine and additionally at least one of
Renal failure
Hepatic insufficiency

Rifampicin

Rifampicin

Simvastatin, lovastatin

at least one of
Simvastatin
Lovastatin

Sildenafil, vardenafil, pulmonary arterial hypertension

at least one of
Sildenafil
Vardenafil
and additionally Pulmonary hypertensive arterial disease

Amiodarone, bepridil, quinidine

at least one of
Amiodarone
Bepridil
Quinidine

Flecainide, propafenone, metoprolol

at least one of
Flecainide
Propafenone
Metoprolol

Astemizole, terfenadine

at least one of
Astemizole
Terfenadine

Dihydroergotamine, ergonovine, ergotamine, methylergonovine

at least one of
Dihydroergotamine
Ergometrine
Ergotamine
Methergine

Cisapride

Cisapride

Pimozide, sertindole, quetiapine, lurasidone

at least one of
Pimozide
Sertindole
Quetiapine
Lurasidone

Midazolam

Midazolam

Triazolam

Triazolam

Alfuzosin

Alfuzosin

St. John’s wort (Hypericum perforatum)

Hypericum perforatum (St John's Wort)

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2020: APTIVUS Soft capsules
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈